Acerta Clinical Trials

Trials

Studies that name Acerta Clinical Trials as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:30 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT03328273 · A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

  Acerta Pharma BV · active not recruiting · Chronic Lymphocytic Leukemia · study director
• Ph1/Ph2
  NCT03205046 · A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

  Acerta Pharma BV · terminated · DLBCL, Richter Syndrome · study director
• Ph3
  NCT02970318 · A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  Acerta Pharma BV · active not recruiting · Chronic Lymphocytic Leukemia · study director
• Ph1
  NCT02717624 · A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

  Acerta Pharma BV · active not recruiting · Mantle Cell Lymphoma (MCL) · study director
• Ph2
  NCT02717611 · A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

  Acerta Pharma BV · active not recruiting · Chronic Lymphocytic Leukemia · study director
• Ph1/Ph2
  NCT02586857 · A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

  Acerta Pharma BV · active not recruiting · Glioblastoma Multiforme · study director
• Ph2
  NCT02537444 · Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

  Acerta Pharma BV · completed · Ovarian Cancer · study director
• Ph3
  NCT02477696 · Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  Acerta Pharma BV · active not recruiting · Chronic Lymphocytic Leukemia · study director
• Ph2
  NCT02454179 · Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

  Acerta Pharma BV · completed · Squamous Cell Carcinoma of the Head and Neck · study director
• Ph2
  NCT02448303 · Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

  Acerta Pharma BV · completed · Carcinoma, Non-Small-Cell Lung · study director
• Ph2
  NCT02387762 · ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

  Acerta Pharma BV · completed · Rheumatoid Arthritis · study director
• Ph2
  NCT02351739 · Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

  Acerta Pharma BV · completed · Metastatic Urothelial Carcinoma · study director
• Ph1
  NCT02211014 · An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

  Acerta Pharma BV · completed · Multiple Myeloma (MM) · study director
• Ph1
  NCT02157324 · Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

  Acerta Pharma BV · active not recruiting · Chronic Lymphocytic Leukemia · study director
• Ph1/Ph2
  NCT02029443 · ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

  Acerta Pharma BV · active not recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome · study director

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.